Convatec, Beta Bionics to launch iLet Bionic Pancreas

Convatec announced that it partnered with Beta Bionics on the launch of the iLet Bionic Pancreas for automated insulin delivery.

FDA last week cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software.

Convatec offers design and manufacturing services for infusion set technologies and insertion devices for insulin pump treatment. Beta Bionics’ iLet uses its inset and contact detach infusion sets for subcutaneous insulin administration.

The company’s inset, an all-in-one infusion set with a built-in insertion device, connects to iLet on one end and the infusion site at the other. It features a soft, indwelling cannula. Convatec’s contact detach comes with a thin, stainless steel needle. Both infusion sets use kink-free infusion tubing to ensure uninterrupted insulin infusion. They also feature a skin-friendly adhesive tape to secure the set firmly at the infusion site.

Convatec intends to manufacture these sets for Beta Bionics at its production sites in Mexico. The company said it’s “pleased to be part” of the launch of the Beta Bionics offering.

“We are pleased to be a part of the iLet Bionic Pancreas system, a truly innovative offering that provides more choice for people with Type 1 diabetes,” said Kjersti Grimsrud, Convatec COO of infusion care. “Convatec has been committed to pioneering diabetes solutions for more than 30 years. This partnership further demonstrates the strength of Convatec’s technology and leadership in infusion solutions. We are delighted to have Beta Bionics in our line-up of professional insulin pump partners, who share our ethos of providing innovative and simplified medical device solutions to patients and healthcare professionals.” Drug Delivery Business